- Home
- DSP vs DTIL Comparison
DSP vs DTIL Comparison
Compare DSP & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DSP | DTIL |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.3M | 194.3M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DSP | DTIL |
|---|---|---|
| Price | $10.60 | $6.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | $17.81 | ★ $45.00 |
| AVG Volume (30 Days) | 179.7K | ★ 203.4K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.14 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | $344,201,000.00 | ★ $1,070,000,000.00 |
| Revenue This Year | $20.27 | N/A |
| Revenue Next Year | $16.88 | N/A |
| P/E Ratio | $29.56 | ★ N/A |
| Revenue Growth | ★ 19.00 | N/A |
| 52 Week Low | $8.11 | $3.53 |
| 52 Week High | $16.25 | $8.82 |
Technical Indicators
Market Signals| Indicator | DSP | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 48.22 | 52.88 |
| Support Level | $8.49 | $4.56 |
| Resistance Level | $10.73 | $7.59 |
| Average True Range (ATR) | 0.69 | 0.45 |
| MACD | -0.04 | -0.10 |
| Stochastic Oscillator | 39.36 | 29.75 |
Price Performance
Historical ComparisonAbout DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).